Oncode Accelerator’s Post

🤖 Quicker detection of breast cancer by AI 🤖   Researchers from the UMC Utrecht, showed that AI pathologists can help to assess the sentinel node in breast cancer patients more efficiently. This assessment is necessary to detect potential metastasis of breast cancer.   Using AI for this detection makes the process more efficient, time saving and cheaper. The pathologists at UMC Utrecht are now working with the AI assistant as standard in breast cancer, probably as the first in the world.   You can read the whole publication in Nature Cancer via the link below 👇 https://lnkd.in/dg7TXn9W

📢 Save the date! 📢 The Oncode Accelerator Summit will be organised on November 28th at the Eye Filmmuseum in Amsterdam. Hear from expert speakers how innovation accelerates the development of new cancer therapies. Gain understanding on the value of demonstrator projects and how to join. Subscribe via the link below to receive updates on speakers and registration👇 https://lnkd.in/eS375kkA

🔬 CAR T-cell therapy further explored 🔬 For a long time, the perception has been that CAR T-cell therapy has little potential in the treatment of solid tumors. However, a recent publication showed that CAR T-cell therapy could have effect in solid tumors. The effect is still limited but there is already follow-up research that gives reason to think that future prospects are better. Workstream lead Cell and Gene therapy, John Haanen, is leader of the immunotherapy research theme and program director of the Center for Cell Therapy at our partner, the Antoni van Leeuwenhoek. He describes the developments in the world of CAR T-cells in the article below. 👇

🌟 Interesting to read! 🌟 Read the first blog by the Oncode Accelerator team on the network of the Federation of European Biochemical Societies (FEBS). The blog will give you more insight about the Innovation Platforms and Workstreams within the program and our first call for Demonstrator Projects. Read the blog via the link below 👇 #FEBS #CancerResearch #Innovation

📢 The first call is open! 📢 In April, Oncode Accelerator announced the opening of the first call for the Demonstrator Projects. What is in it for you? Oncode Accelerator provides you with access to state-of-the-art equipment, world-class research institutes and industry, top scientists, and a dedicated team to manage the process of your Demonstrator Project from the start to the finish. Besides, a Demonstrator Project can receive co-funding from Oncode Accelerator. Oncode Accelerator invites all parties interested in our unique approach to apply for a Demonstrator Project focused on the preclinical development of cancer therapies. Read more about the Demonstrator Projects via the link below 👇

🤖 AI in the detecting of prostate cancer 🤖 Research from one of our partners, Radboudumc, studied the use of an AI model in the detecting of prostate cancer. The study showed that the AI model detects prostate cancer more often and gives fewer false alarms than the radiologist. Using AI could thereby help to prevent unnecessary biopsies. In Sweden and Denmark, AI is also studied for the detection of breast cancer, which so far led to an increase in diagnoses when AI is used. However, AI is not yet used in the clinical setting and it might take a few more years for this to happen. Read the whole research article via this link: https://lnkd.in/enbxT4ya 

🌟 Exciting Opportunity 🌟    Are you passionate about making a difference in cancer therapy development? We are expanding our team and seeking enthusiastic individuals to join us!    Oncode Accelerator foundation is currently looking for a Program Manager Demonstrators to facilitate the different program governance bodies. The Oncode Accelerator program is a cancer research network of 35 organizations that have joined forces innovate and accelerate the development of oncology treatments.    Check our vacancy here 👉 https://lnkd.in/eaPPRehg

🌟 European Hematology Association (EHA) 2024 in Madrid 🌟 Workstream co-lead Cell and Gene Therapy, Jurgen Kuball, will present at the European Hematology Association (EHA) congress in Madrid. Jurgen will present on the GoCART initiative during the European Projects in Hematology session on Sunday June 16th between 8.30 and 9.30 AM. The mission of GoCART is to promote patient access to novel cellular therapies and to contribute to health and well-being through innovation by multi-stakeholder collaboration. Join the meeting and learn more!

🌟 Looking back at a successful event 🌟 Recently, our public and private partners gathered for Oncode Accelerator's first Annual Event. Over 130 experts across different fields in oncology drug development came together to discuss how we can ‘Collaborate to Demonstrate’. We left the meeting with great excitement and have continued the discussions over the last days. We are keen to onboard new partners and demonstrators to join next steps in our journey in outsmarting cancer and improving lives. Read more about what Oncode Accelerator offers on our website: https://lnkd.in/efykuKfe